Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Arterial Hypertension
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 26, No 1 (2022)
REVIEW
Published online: 2021-07-01
View PDF Download PDF file View HTML
Get Citation

Why not change the therapy of hypertension in patients with COVID-19. Dual role of angiotensin-converting enzyme 2

Jerzy Głuszek1, Teresa Kosicka2
DOI: 10.5603/AH.a2021.0014
·
Arterial Hypertension 2022;26(1):1-8.
Affiliations
  1. Calisia University, Kalisz, Poland
  2. Department of Hypertensiology, Angiology and Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland

open access

Vol 26, No 1 (2022)
REVIEW
Published online: 2021-07-01

Abstract

Despite many organizational and medical efforts, the COVID-19 epidemic continues and is taking a lethal toll. Preliminary reports have already reported that the mortality associated with this disease is much higher in people with comorbidities, including hypertension. SARS-CoV-2 virus enters the body through the receptor which is the angiotensin converting enzyme 2 (ACE2). The administration of angiotensin converting enzyme inhibitors or sartans increases the activity of this enzyme. Therefore, there was a suspicion that patients treated with these preparations become more easily infected, and the infection itself is more severe and is associated with greater mortality. On the other hand, the ACE2 enzyme is known to reduce the risk of lung damage. The paper presents current reports describing the frequency of SARS-CoV-2 virus infection in patients with hypertension, the course of infection and the effect of administration of ACE inhibitors and sartans on the mortality of these patients. The presented data indicate that the use of angiotensin converting enzyme inhibitors and sartans in patients with COVID-19 does not worsen the course of the disease, and according to some authors this treatment even reduces the mortality of this infection.

Abstract

Despite many organizational and medical efforts, the COVID-19 epidemic continues and is taking a lethal toll. Preliminary reports have already reported that the mortality associated with this disease is much higher in people with comorbidities, including hypertension. SARS-CoV-2 virus enters the body through the receptor which is the angiotensin converting enzyme 2 (ACE2). The administration of angiotensin converting enzyme inhibitors or sartans increases the activity of this enzyme. Therefore, there was a suspicion that patients treated with these preparations become more easily infected, and the infection itself is more severe and is associated with greater mortality. On the other hand, the ACE2 enzyme is known to reduce the risk of lung damage. The paper presents current reports describing the frequency of SARS-CoV-2 virus infection in patients with hypertension, the course of infection and the effect of administration of ACE inhibitors and sartans on the mortality of these patients. The presented data indicate that the use of angiotensin converting enzyme inhibitors and sartans in patients with COVID-19 does not worsen the course of the disease, and according to some authors this treatment even reduces the mortality of this infection.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

COVID-19; hypertension; angiotensin-converting inhibitors and sartans; angiotensin-converting enzyme 2

About this article
Title

Why not change the therapy of hypertension in patients with COVID-19. Dual role of angiotensin-converting enzyme 2

Journal

Arterial Hypertension

Issue

Vol 26, No 1 (2022)

Pages

1-8

Published online

2021-07-01

Page views

5239

Article views/downloads

554

DOI

10.5603/AH.a2021.0014

Bibliographic record

Arterial Hypertension 2022;26(1):1-8.

Keywords

COVID-19
hypertension
angiotensin-converting inhibitors and sartans
angiotensin-converting enzyme 2

Authors

Jerzy Głuszek
Teresa Kosicka

References (61)
  1. Yang J, Zheng Ya, Gou Xi, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91–95.
    CrossRefPubMed
  2. Cure E, Cumhur Cure M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes Metab Syndr. 2020; 14(4): 349–350.
    CrossRefPubMed
  3. Ciulla MM. Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19. Eur Heart J. 2020; 41(19): 1856.
    CrossRefPubMed
  4. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–280.e8.
    CrossRefPubMed
  5. Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2): 281–292.e6.
    CrossRefPubMed
  6. Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2): 631–637.
    CrossRefPubMed
  7. Dobbs LG. Pulmonary Surfactant. Ann Rev Med. 1989; 40(1): 431–446.
    CrossRef
  8. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11(8): 875–879.
    CrossRefPubMed
  9. Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020; 24(1): 422.
    CrossRefPubMed
  10. Baud D, Qi X, Nielsen-Saines K, et al. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020; 20(7): 773.
    CrossRefPubMed
  11. Uhal BD, Li X, Piasecki CC, et al. Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol. 2012; 44(3): 465–468.
    CrossRefPubMed
  12. Zambelli V, Bellani G, Borsa R, et al. Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. Intensive Care Med Exp. 2015; 3(1): 44.
    CrossRefPubMed
  13. Ye R, Liu Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp Mol Pathol. 2020; 113: 104350.
    CrossRefPubMed
  14. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436(7047): 112–116.
    CrossRefPubMed
  15. Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. Postgrad Med J. 2020; 96(1137): 403–407.
    CrossRefPubMed
  16. Kleinsasser A, Pircher I, Treml B, et al. Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia. Wilderness Environ Med. 2012; 23(1): 24–30.
    CrossRefPubMed
  17. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020; 92(7): 726–730.
    CrossRefPubMed
  18. Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017; 21(1): 234.
    CrossRefPubMed
  19. Wang K, Basu R, Poglitsch M, et al. Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure. Circ Heart Fail. 2020; 13(7): e006939.
    CrossRefPubMed
  20. Adams ML, Katz DL, Grandpre J. Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. Emerg Infect Dis. 2020; 26(8): 1831–1833.
    CrossRefPubMed
  21. Yang J, Zheng Ya, Gou Xi, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91–95.
    CrossRefPubMed
  22. Enami A, Javanmardi F, Pirbonyah N, et al. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020; 8(1): e35.
    PubMed
  23. Wang Z, Chen Z, Zhang L, et al. China Hypertension Survey Investigators. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015. Circulation. 2018; 137(22): 2344–2356.
    CrossRefPubMed
  24. Mancia G, Rea F, Ludergnani M, et al. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; 382(25): 2431–2440.
    CrossRefPubMed
  25. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(15): 458–464.
    CrossRefPubMed
  26. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020; 133(9): 1032–1038.
    CrossRefPubMed
  27. Wang D, Hu Bo, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–1069.
    CrossRefPubMed
  28. Chen C, Chen C, Yan JT, et al. [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020; 48(7): 567–571.
    CrossRefPubMed
  29. Xiang T, Liu J, Xu F, et al. Analysis of clinical characteristics of 49 patients with new type of coronavirus pneumonia in Jiangxi region. Chin J Resp Crit Care. 2020; 19: 154–160.
    CrossRef
  30. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75(7): 1730–1741.
    CrossRefPubMed
  31. Yang J, Zheng Ya, Gou Xi, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91–95.
    CrossRefPubMed
  32. Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020; 12(7): 6049–6057.
    CrossRefPubMed
  33. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020; 130(4): 304–309.
    CrossRefPubMed
  34. Chen R, Liang W, Jiang M, et al. Medical Treatment Expert Group for COVID-19. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest. 2020; 158(1): 97–105.
    CrossRefPubMed
  35. Li G, Li H, Lu J. No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity. Clin Res Cardiol. 2021; 110(1): 146–147.
    CrossRefPubMed
  36. Guan WJ, Liang WH, Zhao Yi, et al. China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55(5).
    CrossRefPubMed
  37. Xu K, Chen Y, Yuan J, et al. Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2020; 71(15): 799–806.
    CrossRefPubMed
  38. Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005; 68(5): 2189–2196.
    CrossRefPubMed
  39. Burchill LJ, Velkoska E, Dean RG, et al. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond). 2012; 123(11): 649–658.
    CrossRefPubMed
  40. Shen L, Mo H, Cai L, et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock. 2009; 31(5): 500–506.
    CrossRefPubMed
  41. Lai CC, Wang YH, Wang CY, et al. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018; 13: 867–874.
    CrossRefPubMed
  42. Spannella F, Giulietti F, Balietti P, et al. Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives. J Am Med Dir Assoc. 2018; 19(4): 342–347.
    CrossRefPubMed
  43. Caldeira D, Alarcão J, Vaz-Carneiro A, et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012; 345: e4260.
    CrossRefPubMed
  44. Siedlinski M, Jozefczuk E, Xu X, et al. White Blood Cells and Blood Pressure: A Mendelian Randomization Study. Circulation. 2020; 141(16): 1307–1317.
    CrossRefPubMed
  45. Youn JC, Yu HT, Lim BJ, et al. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013; 62(1): 126–133.
    CrossRefPubMed
  46. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today. 2006; 11(11-12): 524–533.
    CrossRefPubMed
  47. Henry C, Zaizafoun M, Stock E, et al. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018; 31(4): 419–423.
    CrossRefPubMed
  48. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020; 126(12): 1671–1681.
    CrossRefPubMed
  49. Li J, Wang X, Chen J, et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020; 5(7): 825–830.
    CrossRefPubMed
  50. Mancia G, Rea F, Ludergnani M, et al. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; 382(25): 2431–2440.
    CrossRefPubMed
  51. Zhang X, Yu J, Pan LY, et al. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Pharmacol Res. 2020; 158: 104927.
    CrossRefPubMed
  52. Guo X, Zhu Y, Hong Y. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. Hypertension. 2020; 76(2): e13–e14.
    CrossRefPubMed
  53. Flacco ME, Acuti Martellucci C, Bravi F, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020; 106(19): 1519–1524.
    CrossRefPubMed
  54. Greco A, Buccheri S, D'Arrigo P, et al. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020; 6(5): 335–337.
    CrossRefPubMed
  55. Pranata R, Permana H, Huang I, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Diabetes Metab Syndr. 2020; 14(5): 983–990.
    CrossRefPubMed
  56. Pirola CJ, Sookoian S. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. J Infect. 2020; 81(2): 276–281.
    CrossRefPubMed
  57. Baral R, White M, Vassiliou VS. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients. Curr Atheroscler Rep. 2020; 22(10): 61.
    CrossRefPubMed
  58. Patoulias D, Katsimardou A, Stavropoulos K, et al. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Curr Hypertens Rep. 2020; 22(11): 90.
    CrossRefPubMed
  59. Atalay C, Dogan N, Aykan S, et al. The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. Singapore Med J. 2010; 51(6): 501–505.
    PubMed
  60. Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
    CrossRefPubMed
  61. Zhang XJ, Qin JJ, Cheng Xu, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020; 32(2): 176–187.e4.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl